Medical treatment and postoperative management of thyroid carcinoma;Medikamentose therapie und Nachsorge von Schilddrusenkarzinomen

Tumor Diagnostik und Therapie

Volumn 19, Issue 3, 1998, Pages 79-85

  Pfeilschifter, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

(131)I whole body scans; Calcitonin; Multiple endocrine neoplasia type II; Postoperative care; Thyroglobulin; Thyroid Carcinoma; TSH suppressive treatment

Indexed keywords

IODINE 131; LEVOTHYROXINE; THYROGLOBULIN;

ARTICLE; FOLLOW UP; HORMONE INHIBITION; HUMAN; POSTOPERATIVE PERIOD; RADIOISOTOPE THERAPY; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY AUTORADIOGRAPHY;

EID: 0031717277     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Abdelmoumene, N, Schlumberger, M, Gardet P et al.: Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br. J. Cancer 69 (1994) 1141-1144.
2. Bakheet, SM, Pow, JE, Hammami MM et al.: Comparison of F-18 FDG to I-123 and I-131 scans in thyroid carcinoma. Clin. Nucl. Med. 22 (1997) 438-439
3. Biondi, B, Fazio, S, Carella C et al.: Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 78 (1994) 1028-1033
4. Biondi, B, Fazio, S, Cuocolo A et al.: Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 81 (1996): 4224-4228
5. Blondeau, P: Is thyroid cancer a severe cancer? Bull. Acad. Natl. Med. 776 (1992) 1087-1093
6. Bonnin, F, Schlumberger, M, Gardet P et al.: Screening for adrenal medullary disease in patients with medullary thyroid carcinoma. J. Endocrinol. Invest. 17 (1994) 253-257
7. 99mTc pertechnetate for detecting metastases of differentiated thyroid carcinoma. Clin. Nucl. Med. 15 (1990) 1-4
8. Chariot, P, Feliz AA, Monnet I: Miliary opacities diagnosed as lung metastases of a thyroid carcinoma after 13 years of stability. Chest 104 (1993) 981-982
9. De Besi, P, Busnardo, B, Toso S et al.: Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J. Endocrinol. Invest. 74 (1991) 475-480
10. Demeter, JG, De Long, SA, Lawrence AM et al.: Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 110 (1991) 956-963
11. Dinneen, SF, Valimaki, MJ, Bergstralh EJ et al.: Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J. Clin. Endocrinol. Metab. 80 (1995) 2041-2045
12. Dulgeroff AJ, Hershman, JM: Medical therapy for differentiated thyroid carcinoma. Endocr. Reviews. 15 (1994) 500-515
13. 99mTc-MIBI zur Rezidivund Metastasensuche bei differenzierten Schilddrüsenkarzinomen. Nuklearmedizin 36 (1997) 7-12
14. Fleisch, H: Bisphosponates in bone disease, S. 86-110. The Parthenon Publishing Group, Lancs 1995
15. Franceschi, M, Kusic, Z, Franceschi, D et al.: Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J. Nucl. Med. 37 (1996) 446-451
16. Frank-Raue, K, Raue, F. Buhr HJ et al.: Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2 (1992) 113-117
17. Frank-Raue, K, Ziegler, R, Raue, F: The use of octreotide in the treatment of medullary thyroid carcinoma. Horm. Metab. Res., Suppl. 27 (1993) 44-47
18. Frilling, A, Dralle, H, Eng C et al.: Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 118 (1995) 1099-1103
19. Gagel, RF: Multiple endocrine neoplasia type II and familial medullary thyroid carcinoma. Impact of genetic screening on management. Cancer Treat. Res. 89 (1997) 412-441
20. Gorres, G, Kaim, A, Otte, A et al.: Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur. J. Nucl. Med. 23 (1996) 690-692
21. Japanese Society of Thyroid Surgery, Chemotherapy Committee: Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte colony-stimulating factor support. Jpn. J. Clin. Oncol. 25 (1995) 203-207
22. Joseph, U, Schmidt, JA, Ehlenz, K et al.: Iodine-induced hyperthyroidism in metastatic thyroid carcinoma. Dtsch. Med. Wochenschr. 18 (1994) 1573-1578
23. Kasagi, K, Takeuchi, R, Miyamoto, S et al.: Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin. Endocrinol. 40 (1994) 429-434
24. Kumar, A, Shah, DH, Shrihari, U et al.: Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 4 (1994) 199-202
25. Lubin, E, Mechlis-Frish, S, Zatz, S et al.: Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J. Nucl. Med. 35 (1994) 257-262
26. Mahler, C, Verhelst, J, de Longueville, M et al.: Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin. Endocrinol. 33 (1990) 261-269
27. Meier, CA, Braverman, LE, Ebner, SA et al.: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J. Clin. Endocrinol. Metab. 78 (1994) 188-196
28. Modigliani E, Vasen, HM, Raue, K et al.: Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J. Intern. Med. 238 (1995) 363-367
29. Muller, CG, Bayley, TA, Harrison, JE et al.: Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 5 (1995) 81-87
30. Niederle, B, Roka, R, Schemper, M et al: Surgical treatment of distant metastases in differentiated thyroid cancer: indications and results. Surgery 100 (1986) 1088-1097
31. Orlandi, F, Caraci, P, Berruti, A et al.: Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann. Oncol. 5 (1994) 763-765
32. Pacini, F, Cetani, F, Miccoli, P et al.: Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J. Surg. 18 (1994) 600-604
33. Pelizzo, MR, Busnardo, B, Bernante, P et al.: Medullary thyroid carcinoma: prognostic factors. Minerva Chir. 48 (1993) 1289-1291
34. Pineda, JD, Lee, T, Ain, K et al.: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J. Clin. Endocrinol. Metab. 80 (1995) 1488-1492
35. Proye, CA, Dromer, DH, Carnaille, BM et al.: Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J. Surg. 16 (1992) 640-646
36. Pujol, P, Daures, J-P, Nsakala, N et al.: Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81 (1996) 4318-4323
37. Raue, F, Kraimps, JL, Dralle, H et al.: Primary hyperparathyroidism in multiple endocrine neoplasia type 2 A. J. Intern. Med. 238 (1995) 369-373
38. Ringel, MD, Ladenson, PW: Diagnostic accuracy of 1311 scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J. Clin. Endocrinol. Metab. 81 (1996):1724-1725
39. Samman, NA, Schultz, PN, Hickey, RC et al.: The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J. Clin. Endocrinol. Metab. 75 (1992) 714-720
40. Sawin, CT, Geller, A, Wolf, PA et al.: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331 (1993) 1249-1252
41. Scherübl, H, Raue, F, Ziegler, R: Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J. Cancer Res. Clin. Oncol. 116 (1990) 21-23
42. Schicha, H, Dietlein, M: Radioiodine therapy in differentiated thyroid gland carcinoma. Zentralbl. Chir. 122 (1997) 266-273
43. Schlumberger, M, Challeton, C, De-Vathaire, F et al.: Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37 (1996) 598-605
44. Shaha, AR; Loree, TR, Shah, JP: Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118 (1995) 1131-1136
45. Simon, D, Köhrle, J, Schmutzler, C et al.: Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp. Clin. Endocrinol. Diabetes 104, Suppl. 4 (1996) 13-15
46. Sisson, JC, Ackermann, RJ, Meyer, MA et al.: Uptake of 18-fluoro2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J. Clin. Endocrinol. Metab. 77 (1993) 1090-1094
47. Sisson, JC, Giordano, TJ, Jamadar, DA et al.: 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 78 (1996) 2184-2192
48. Smid. WM, Dullaart, RP: Octreotide for medullary thyroid carcinoma associated diarrhoea. Neth. J. Med. 40 (1992) 240-243
49. Spencer, CA, Wang, CC: Thyroglobulin measurements. Techniques, clinical benefits, and pitfalls. Endocrinol. Metab. Clin. North Am. 24 (1995) 841-863
50. Spencer, CA, Takeuchi, M, Kazarosyan, M: Current status and performance goals for serum thyrogobulin assays. Clin. Chem. 42 (1996) 164-173
51. Tamaki, H, Amino, N, Takeoka, K et al.: Thyroxine requirement during pregnancy for replacement of hypothyroidism. Obstet. Gynecol. 76 (1990) 230-233
52. Tenenbaum, F, Schlumberger, M, Bonnin, F et al.: Usefulness of technetium-99 m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma. Eur. J. Nucl. Med. 20 (1993) 1168-1174
53. Tennvall, J, Lundell, G, Hallquist, A et al.: Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. Cancer 74 (1994) 1348-1354
54. Tisell, LE, Dilley, WG, Wells, SA Jr.: Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 119 (1996) 34-39
55. Tumorzentrum Heidelberg/Mannheim: Das Schilddrüsenkarzinom. Schriftenreihe des Tumorzentrums Heidelberg/Mannheim (1993) 1-26
56. Ugur O, Kostakglu, L, Guler, N et al.: Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur. J. Nucl. Med. 23 (1996) 1367-1371
57. Uzzan, B, Campos, J, Cucherat, M et al.: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J. Clin. Endocrinol. Metab. 81 (1996) 4278-4289
58. Van Heerden, JA, Grant, CS, Gharib, H et al.: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 212 (1990) 395-401
59. Vassilopoulou-Sellin, R, Schultz, PN, Haynie, TP: Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78 (1996) 493-501
60. Wood WJ, Singletary, SE, Hickey, RC: Current results of treatment for distant metastatic well-differentiated thyroid carcinoma. Arch. Surg. 124 (1989) 1374-1377
61. Wu, LT, Averbuch, SD, Ball, DW et al.: Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. Cancer 73 (1994) 432-436